Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499924 | 0.87 | HTT (0.64) | HTTKDM4EALDH1A1STAT3CYP1A2 | |
| SCHEMBL16884151 | 0.85 | GAA (0.63) | KDM4EALDH1A1 | |
| SCHEMBL28191613 | 0.83 | GAA (0.66) | KDM4EALDH1A1 | |
| SCHEMBL30385718 | 0.83 | HTR2A (0.63) | HTTKDM4ETDP1 | |
| SCHEMBL29039328 | 0.83 | HTR2A (0.63) | HTTKDM4ETDP1 | |
| SCHEMBL3377384 | 0.81 | KDM4E (0.64) | KDM4EALDH1A1TDP1CYP1A2 | |
| SCHEMBL8325210 | 0.81 | ALDH1A1 (0.63) | HTTALDH1A1 | |
| SCHEMBL4709200 | 0.81 | HTT (0.62) | HTTKDM4EALDH1A1STAT3CYP1A2 | |
| SCHEMBL2016911 | 0.80 | L3MBTL1 (0.55) | HTTKDM4EALDH1A1STAT3 | |
| SCHEMBL7958862 | 0.80 | HTT (0.64) | HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028603-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| EP-2491035-B1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9161934-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8962652-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8507507-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2491035-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049825-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | HTT 4624/4885KDM4E 3501/4885ALDH1A1 963/4885 |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | HTT 4624/4885KDM4E 3501/4885ALDH1A1 963/4885 |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | HTT 4577/4885KDM4E 3699/4885ALDH1A1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.